Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... These frameworks provide patients and developers with legal protection by simplifying liability standards ...

We are maintaining Eli Lilly’s Uncertainty Rating ... encounters considerable regulatory and legal risks, including product approvals, patent challenges, and liability lawsuits.

US President Donald Trump signed an executive order requiring drugmakers to lower prices, aligning with international rates.

Shares of Alphamab Oncology plunged 14.4% to HK$6.28, leading declines in Hong Kong-listed pharmaceutical stocks.Meanwhile, ...

Novo Nordisk and Eli Lilly , the leaders in the highly ... drug prices would be difficult to implement and face legal challenges. Roche boosts US presence with new $700 million North Carolina ...

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...

It's plainly apparent that Novo Nordisk has had May 22 circled its calendar since February, when the FDA began the countdown ...

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.